Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty
ACTRN12609000762257Phase 4Completed
- Sponsor
- Launceston General Hospital
- Start
- Jan 2010
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivaroxaban and enoxaparin in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) (2 arms), sponsored by Launceston General Hospital. Primary endpoints: Postoperative micro-bleeding composite assessment and Other postoperative bleeding. Started Jan 2010; status: completed.
02
Drugs
rivaroxabanenoxaparin
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on ACTRN12609000762257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000762257.